Login to Your Account

Personalized Medicine Market Reaching Its Adolescence

By Jonathan Goldstein
BioWorld Today Contributing Writer

Monday, April 29, 2013
WASHINGTON – While the intrinsic value of using companion diagnostics to target the right drugs to the right patients is recognized by all components of the health care system, including drugmakers, diagnostic developers, clinician and patient interest groups and payers, more cohesion is needed among all those parties – and at earlier stages in development – for personalized medicine to reach its potential value.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription